

## ECRG2 Antibody Catalog # ASC11386

### Specification

#### ECRG2 Antibody - Product Information

Application	WB, IHC-P, E
Primary Accession	<a href="#">P58062</a>
Other Accession	<a href="#">AAI09386, 14211875</a>
Reactivity	Human, Mouse, Rat
Host	Chicken
Clonality	Polyclonal
Isotype	IgY
Application Notes	ECRG2 antibody can be used for detection of ECRG2 by Western blot at 1 µg/mL. Antibody can also be used for immunohistochemistry starting at 5 µg/mL.

#### ECRG2 Antibody - Additional Information

Gene ID **84651**

#### Target/Specificity

SPINK7; ECRG2 antibody is predicted to not cross-react with other ECRG family members

#### Reconstitution & Storage

ECRG2 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

#### Precautions

ECRG2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

#### ECRG2 Antibody - Protein Information

Name SPINK7

Synonyms ECG2

#### Function

Probable serine protease inhibitor.

#### Cellular Location


Secreted.

#### ECRG2 Antibody - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### ECRG2 Antibody - Images



Western blot analysis of ECRG2 in human lung tissue lysate with ECRG2 antibody at 1 µg/mL in (A) the absence and (B) the presence of blocking peptide.



Immunohistochemistry of ECRG2 in rat lung tissue with ECRG2 antibody at 5 µg/mL.

### ECRG2 Antibody - Background

**ECRG2 Antibody:** The esophageal cancer-susceptibility gene 2 (ECRG2), also known as SPINK7, is a novel tumor suppressor gene identified from the human esophagus. It interacts directly with metallothionein 2A and urokinase-type plasminogen activator (uPA), and downregulates the activity of uPA, leading to reduced cancer cell migration, invasion and metastasis. ECRG2 forms a complex with uPA and its receptor uPAR, modifying the dynamic association of uPAR with beta1 integrins and disrupting the Src/MAP kinase pathway that normally stimulates cell migration and invasion. ECRG2 may thus represent a novel therapeutic target for cancer.

## ECRG2 Antibody - References

Cui Y, Wang J, Zhang X, et al. ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis. *Biochem. Biophys. Res. Commun.* 2003; 302:904-15.

Huang G, Hu Z, Li M, et al. ECRG2 inhibits cancer cell migration, invasion and metastasis through the down-regulation of uPA/plasmin activity. *Carcinogenesis* 2007; 28:2274-81

Cheng X, Shen Z, Yin L, et al. ECRG2 regulates cell migration/invasion through the urokinase-type plasmin activator receptor (uPAR)/beta1 integrin pathway. *J. Biol. Chem.* 2009; 284:30897-906